Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017096341) ADENOVIRUS-VECTORED MULTIVALENT VACCINE
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/096341 International Application No.: PCT/US2016/064880
Publication Date: 08.06.2017 International Filing Date: 05.12.2016
IPC:
C07K 14/705 (2006.01) ,A61K 39/12 (2006.01) ,C12N 15/63 (2006.01) ,C12N 15/86 (2006.01) ,C12N 15/861 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
705
Receptors; Cell surface antigens; Cell surface determinants
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
12
Viral antigens
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
63
Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
63
Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79
Vectors or expression systems specially adapted for eukaryotic hosts
85
for animal cells
86
Viral vectors
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
63
Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79
Vectors or expression systems specially adapted for eukaryotic hosts
85
for animal cells
86
Viral vectors
861
Adenoviral vectors
Applicants:
THE TEXAS A&M UNIVERSITY SYSTEM [US/US]; 3369 Tamu College Station, TX 77843-3369, US
Inventors:
MWANGI, Waithaka; US
WAGHELA, Suryakant, D.; US
LOKHANDWALA, Shehnaz, T.; US
BRAY, Jocelyne, M.; US
Agent:
EISENSCHENK, Frank, C.; US
SALIWANCHIK, David, R.; US
PARKER, James, S; US
LLOYOD, Jeff; US
LADWIG, Glenn, P.; US
Priority Data:
62/263,42404.12.2015US
Title (EN) ADENOVIRUS-VECTORED MULTIVALENT VACCINE
(FR) VACCIN POLYVALENT À VECTEUR ADÉNOVIRAL
Abstract:
(EN) The invention pertains to a vaccine comprising an immunologically effective amount of a novel live-vectored multivalent vaccine formulation that affords immunization to multiple antigens of a pathogen that is relatively impervious to vaccine development by providing multiple virus-expressed antigens and a pharmaceutically acceptable carrier and/or an adjuvant. Further, a method of immunizing a subject against an exposure to a pathogen that is relatively impervious to vaccine development is provided, wherein the method comprising the steps of administering the vaccine to a subject to induce an immune response against antigenic proteins or fragments thereof.
(FR) L'invention concerne un vaccin comprenant une quantité immunologiquement efficace d'une nouvelle formulation de vaccin polyvalent à vecteur vivant qui permet d'immuniser contre les multiples antigènes d'un pathogène qui est relativement insensible au développement de vaccins par utilisation de multiples antigènes exprimés par les virus et un véhicule et/ou un adjuvant pharmaceutiquement acceptable. Une méthode d'immunisation d'un sujet contre une exposition à un pathogène qui est relativement insensible au développement de vaccins est en outre décrite, la méthode comprenant les étapes d'administration du vaccin à un sujet pour induire une réponse immunitaire contre des protéines antigéniques ou des fragments de celles-ci.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)